Chlorambucil 2 mg tablets
Sponsors
F. Hoffmann-La Roche AG, Acerta Pharma B.V.
Conditions
Chronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia (CLL)
Phase 3
A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL and Coexisting Medical Conditions
CompletedCTIS2023-504034-22-00
Start: 2014-12-18End: 2025-08-06Target: 267Updated: 2025-06-27
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia
Active, not recruitingCTIS2023-509348-84-00
Start: 2015-04-27Target: 212Updated: 2025-12-22